Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 10 Sep 2022
Your money or your life? Cancer’s crushing cost
10 September 2022 - The first thing many cancer patients see when they arrive at the oncology ward is the EFTPOS ...
Posted by Michael Wonder on 09 Sep 2022
Health Canada approves Pfizer-BioNTech COVID-19 vaccine for kids under 5
9 September 2022 - Health Canada approves Pfizer-BioNTech COVID-19 vaccine for kids under 5. ...
Posted by Michael Wonder on 09 Sep 2022
Bausch Health responds to Norwich Pharmaceuticals tentative FDA approval for a 200 mg rifaximin
9 September 2022 - Bausch Health and its gastro-enterology business Salix Pharmaceuticals today responded to the US FDA's tentative approval ...
Posted by Michael Wonder on 09 Sep 2022
Spectrum Pharmaceuticals receives FDA approval for Rolvedon (eflapegrastim-xnst) injection
9 September 2022 - First novel long-acting G-CSF product approved in over 20 years. ...
Posted by Michael Wonder on 09 Sep 2022
FDA and EMA accept regulatory submission for Pfizer’s ritlecitinib for individuals 12 years and older with alopecia areata
9 September 2022 - Filings based on clinical data demonstrating significant scalp hair regrowth versus placebo. ...
Posted by Michael Wonder on 09 Sep 2022
Rare cancer sufferers fight to get drugs on PBS
9 September 2022 - People with rare cancers are being forced to sell their homes, raid their superannuation and fundraise ...
Posted by Michael Wonder on 09 Sep 2022
B.C. family grateful for expanded funding to cystic fibrosis drug, but questions why it took so long
7 September 2022 - B.C. is last Canadian jurisdiction to fund Trikafta for patients with cystic fibrosis age 6 to 11. ...
Posted by Michael Wonder on 09 Sep 2022
PBAC Public Summary Documents (first time rejections and deferrals) - May 2022 meeting
9 September 2022 - The Public Summary Documents (first time rejections and deferrals) from the May 2022 PBAC meeting are now ...
Posted by Michael Wonder on 08 Sep 2022
Large scale population based surveys linked to administrative health databases as a source of data on health utilities in Australia
8 September 2022 - It is ideal that modelling studies apply health utility values that are compatible, derived using common methods, ...
Posted by Michael Wonder on 08 Sep 2022
'Long-term harm' for diabetics unable to access medication
8 September 2022 - Diabetic patients could need liver transplants down the line due to the shortage of a life-altering ...
Posted by Michael Wonder on 08 Sep 2022
Launch prices: tackling the next drug pricing challenge
8 September 2022 - The passage of the Inflation Reduction Act brings a new era to drug pricing in the ...
Posted by Michael Wonder on 08 Sep 2022
Is IQWiG's 15% threshold universally applicable in assessing the clinical relevance of patient reported outcomes changes? An ISPOR Special Interest Group report.
8 September 2022 - To assess the clinical relevance of patient reported outcomes, a response threshold of ≥ 15% of the ...
Posted by Michael Wonder on 08 Sep 2022
Esketamine: NICE’s appraisal was unfair, appeal panel rules
8 September 2022 - The decision by the UK National Institute for Health and Care Excellence not to recommend esketamine ...
Posted by Michael Wonder on 08 Sep 2022
British Colombia expands children’s access to ‘transformational’ cystic fibrosis drug
7 September 2022 - A week after a B.C. family went public with its plea for a life-changing drug for ...
Posted by Michael Wonder on 08 Sep 2022
Ceribell receives FDA breakthrough device designation for delirium indication
8 September 2022 - Breakthrough device designation recognizes Ceribell's point of care EEG as a first of its kind technology ...